Interv Akut Kardiol 2011; 10(5-6): 254-255

The PRODIGY study: at last we know how to treat with clopidogrel after coronary angioplasty

Ivo Varvařovský1, Tomáš Janota2
1 Kardiologické centrum Agel, Pardubice
2 III. interní klinika Všeobecné fakultní nemocnice 1. LF UK, Praha

The PRODIGY study is the first randomized prospective study to compare short-term (6 months) and long-term (24 months) dual antiplatelet

therapy after coronary stent implantation. Prevention of ischaemic complications in patients is comparable in both types of treatment.

Long-term dual antiplatelet therapy results in a significantly higher rate of severe bleeding complications and this risk increases with

the duration of treatment. The facts revealed are serious and should lead to modifications of the guidelines for the treatment of patients

after coronary stent implantation.

Keywords: clopidogrel, drug-eluting stents, dual antiplatelet therapy

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I, Janota T. The PRODIGY study: at last we know how to treat with clopidogrel after coronary angioplasty. Interv Akut Kardiol. 2011;10(5-6):254-255.
Download citation

References

  1. Valgimigli M. Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study. ESC Congress 2011, Hot Line III, 30. 8. 2011, Paris.
  2. White HD. Do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer? Curr Opin Cardiol 2011; 26: 275-278. Go to original source... Go to PubMed...
  3. Wijns W, Kolh P, Danchin N. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.